
BNTC Stock Forecast & Price Target
BNTC Analyst Ratings
Bulls say
Benitec Biopharma is positioned attractively because BB-301 is targeting OPMD, a rare disease with no approved disease-modifying therapy and only limited symptomatic options, giving the program a clear unmet-need advantage. The company’s Ph1b/2a data and ESGCT updates showed robust, durable swallowing-function improvements and a 100% responder rate, while FDA discussions in 1Q27 support a pivotal Phase 3 design that management expects to finalize for a mid-2027 start. Financially, Benitec ended September with about $176M in cash, which should fund execution through major regulatory milestones and support its “silence-and-replace” strategy.
Bears say
Benitec Biopharma is viewed negatively because its operating expenses and cash burn have been greater than expected, signaling a business model that is still heavily dependent on external funding rather than self-sustaining operations. As a clinical-stage biotechnology company focused on developing BB-301 for OPMD, it has yet to demonstrate commercial revenue, leaving the investment case tied to uncertain clinical progress and the long duration typical of genetic medicine development. The need for equity issuances more frequently or at less attractive valuations than projected raises dilution risk for shareholders and suggests that financial discipline may remain strained as development costs continue to outpace available resources.
This aggregate rating is based on analysts' research of Benitec Biopharma Limited Sponsored ADR and is not a guaranteed prediction by Public.com or investment advice.
BNTC Analyst Forecast & Price Prediction
Start investing in BNTC
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Benitec Biopharma Limited Sponsored ADR (BNTC) Forecast
BNTC Analyst Forecast & Price Prediction
Start investing in BNTC
Order type
Buy in
Order amount
Est. shares
0 shares